Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.

Autor:	Pablos, Jose L., Abasolo, Lydia, Alvaro-Gracia, Jose M., Blanco, Francisco J., Blanco, Ricardo, Castrejón, Isabel, Fernandez-Fernandez, David, Fernandez-Gutierrez, Benjamín, Galindo-Izquierdo, María, Gonzalez-Gay, Miguel A., Manrique-Arija, Sara, Mena Vázquez, Natalia, Varela, Antonio Mera, Retuerto, Miriam, Seijas-Lopez, Alvaro, Mera Varela, Antonio, RIER investigators group
Předmět:	DRUG therapy for rheumatism VIRAL pneumonia RESEARCH RESEARCH methodology AUTOIMMUNE diseases COVID-19 RETROSPECTIVE studies EVALUATION research MEDICAL cooperation ANTIRHEUMATIC agents COMPARATIVE studies HOSPITAL care RHEUMATOID arthritis DISEASE prevalence EPIDEMICS RHEUMATISM SYSTEMIC lupus erythematosus DEMOGRAPHY POLYMERASE chain reaction
Zdroj:	Annals of the Rheumatic Diseases; Sep2020, Vol. 79 Issue 9, p1170-1173, 4p
Abstrakt:	Background: The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown.Methods: We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups.Results: Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution.Conclusion: Patients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu